

K021514



**PHILIPS**

MAY 16 2002

EXHIBIT 2

**Philips Lighting Company**

---

**510K SUMMARY STATEMENT**

**Company Name:** Philips Lighting Company  
200 Franklin Square Drive  
Somerset, NJ 08875-6800

**Contact:** Toni J. Hoffmann  
Corporate Quality Analyst

**Telephone:** 732-563-3081

**Trade Names:** **Philips PL-S 9W/12/2P UV-B**

**Common Name:** **UVB Lamps**

**Classification:** **Light, Ultraviolet, Dermatological**

**Description:** **Philips PL-S 9W/12/2P UV-B**  
**Watts - 9**  
**Volts - 60**  
**Base - G23**  
**Length - max OAL - 167 mm**

**Intended Use:** **The intended function of the UV-B ultraviolet lamp is therapy for Psoriasis and Vitiligo.**

**Equivalence:** **Substantial equivalence previous devices. Lamps are different dimensionally but have substantially equivalent outputs.**  
**TL20W/12/RS TL40W/12/RS**  
**TL100W/12 UV-B**

**Ref: FDA-510K Summary Statement**  
**File: 14.01.23**



A division of  
Philips Electronics North America Corporation

200 Franklin Square Drive  
P.O. Box 6800  
Somerset, NJ 08875-6800  
Tel: (732) 563-3000



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

MAY 16 2002

Ms. Toni J. Hoffman  
Corporate Quality Analyst  
Philips Lighting Company  
200 Franklin Square Drive  
Somerset, NJ 08875-6800

Re: K021514  
Trade/Device Name: Philips PLS9W/12/2P UV-B  
Regulation Number: 878.4630  
Regulation Name: Ultraviolet lamp for dermatologic disorders  
Regulatory Class: II  
Product Code: FTC  
Dated: May 7, 2002  
Received: May 9, 2002

Dear Ms. Hoffman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

*Miriam C. Provost*

for Celia M. Witten, Ph.D., M.D.  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure



# PHILIPS

**Philips Lighting Company**

---

EXHIBIT 3

## INDICATION FOR USE STATEMENT

510(k) Number (if known): K021514

Device Name: Philips PLS9W/12/2P UV-B

The intended function of the UV-B ultraviolet lamp is therapy for Psoriasis and Vitiligo.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of DCRH, Office of Device Evaluation (ODE)

Miriam C. Provost  
(Division Sign-Off)  
Division of General, Restorative  
and Neurological Devices

Prescription Use  510(k) Number K021514 OR Over-the-Counter Use   
(Per 21 CFR 8001.109) (Optional Format 1-2-96)



A division of  
Philips Electronics North America Corporation

200 Franklin Square Drive  
P.O. Box 6800  
Somerset, NJ 08875-6800  
Tel: (732) 563-3000